Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03752684 · ClinicalTrials.gov registry record · NA
Oxalobacter Formigenes Colonization and Urinary Oxalate Excretion
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT03752684: Completed NA study, sponsored by University of Alabama at Birmingham.
NCT03752684 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03752684, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this research study is to assess the efficacy of ingesting a small amount of the harmless bacterium Oxalobacter formigenes in establishing residence in the guts of healthy participants and to determine whether this influences the oxalate passed in urine.
Primary Outcome
Mean 24-hour urine oxalate excretion after colonization with O.formigenes was compared with mean 24-hour urine oxalate before colonization
Interventions
- DIETARY_SUPPLEMENT Moderately high oxalate/low calcium diet non-colonized
- DIETARY_SUPPLEMENT Oxalobacter formigenes
- DIETARY_SUPPLEMENT Moderately high oxalate/low calcium diet colonized
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2025-05-22 |
| Phase | NA |
What the finished NCT03752684 record still lists
NCT03752684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Moderately high oxalate/low calcium diet non-colonized is the first listed.
NCT03752684 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03752684 about?
NCT03752684 is a clinical study titled "Oxalobacter Formigenes Colonization and Urinary Oxalate Excretion". The purpose of this research study is to assess the efficacy of ingesting a small amount of the harmless bacterium Oxalobacter formigenes in establishing residence in the guts of healthy participants and to determine whether this influences the oxalate passed in urine.
What is the current status of trial NCT03752684?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2018-04-02. Estimated completion is 2025-05-22.
What interventions are being tested in trial NCT03752684?
The interventions under investigation include: Moderately high oxalate/low calcium diet non-colonized (DIETARY_SUPPLEMENT), Oxalobacter formigenes (DIETARY_SUPPLEMENT), Moderately high oxalate/low calcium diet colonized (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03752684?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03752684's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI